Amphastar Pharmaceuticals 

$27.92
281
+$1.43+5.4% Today

Statistics

Day High
28.13
Day Low
26.34
52W High
34.39
52W Low
20.39
Volume
433,403
Avg. Volume
387,685
Mkt Cap
1.28B
P/E Ratio
9.55
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4MarExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
0.69
0.79
0.89
0.99
Expected EPS
0.925271
Actual EPS
N/A

Financials

21.79%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
1.46BRevenue
319.04MNet Income

Analyst Ratings

$30.25Average Price Target
The highest estimate is 34.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
25%
Hold
75%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AMPH. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

About

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Show more...
CEO
Dr. Ziping Luo Ph.D.
Employees
2028
Country
US
ISIN
US03209R1032

Listings

0 Comments

Share your thoughts

FAQ

What is Amphastar Pharmaceuticals stock price today?
The current price of AMPH is $27.92 USD — it has increased by +5.4% in the past 24 hours. Watch Amphastar Pharmaceuticals stock price performance more closely on the chart.
What is Amphastar Pharmaceuticals stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Amphastar Pharmaceuticals stocks are traded under the ticker AMPH.
Is Amphastar Pharmaceuticals stock price growing?
AMPH stock has risen by +4.96% compared to the previous week, the month change is a +5.52% rise, over the last year Amphastar Pharmaceuticals has showed a -19.93% decrease.
What is Amphastar Pharmaceuticals market cap?
Today Amphastar Pharmaceuticals has the market capitalization of 1.28B
When is the next Amphastar Pharmaceuticals earnings date?
Amphastar Pharmaceuticals is going to release the next earnings report on March 04, 2026.
What were Amphastar Pharmaceuticals earnings last quarter?
AMPH earnings for the last quarter are 0.93 USD per share, whereas the estimation was 0.83 USD resulting in a +12.68% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Amphastar Pharmaceuticals revenue for the last year?
Amphastar Pharmaceuticals revenue for the last year amounts to 1.46B USD.
What is Amphastar Pharmaceuticals net income for the last year?
AMPH net income for the last year is 319.04M USD.
How many employees does Amphastar Pharmaceuticals have?
As of February 02, 2026, the company has 2,028 employees.
In which sector is Amphastar Pharmaceuticals located?
Amphastar Pharmaceuticals operates in the Health Care sector.
When did Amphastar Pharmaceuticals complete a stock split?
Amphastar Pharmaceuticals has not had any recent stock splits.
Where is Amphastar Pharmaceuticals headquartered?
Amphastar Pharmaceuticals is headquartered in Rancho Cucamonga, US.